Market Place
Sourcing Support
Palatin Completes Enrollment in Bremelanotide Obesity Study
31 Oct 2024 //
PR NEWSWIRE
Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial
23 Aug 2024 //
PR NEWSWIRE
Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment
20 Jun 2024 //
PR NEWSWIRE
Palatin Initiates Phase 2 Study Of Bremelanotide For Obesity
12 Jun 2024 //
PR NEWSWIRE
Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies Inc.
03 Jan 2024 //
BUSINESSWIRE
Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
02 Jan 2024 //
INDIAN PHARMA POST
Palatin Completes Sale of Vyleesi® to Cosette Pharma for up to $171 Million
20 Dec 2023 //
PR NEWSWIRE
Palatin Announces Preliminary Q4 Fiscal 2023 Vyleesi® Product Revenue Results
11 Jul 2023 //
PR NEWSWIRE
Palatin Issued Patent on Vyleesi For Hypoactive Sexual Desire Disorder
28 Feb 2023 //
PR NEWSWIRE
Palatin Initiates Enrollment in PII Bremelanotide BREAKOUT Study
19 Jan 2023 //
PR NEWSWIRE
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi
05 Jan 2023 //
PR NEWSWIRE
Palatin Announces Publication of Vyleesi fMRI Study in Women with HSDD
17 Oct 2022 //
PRNEWSWIRE
Enforcement Report - Week of April 27, 2022
27 Apr 2022 //
FDA
Palatin Technologies Announces Mutual Termination of License Agreement with AMAG
27 Jul 2020 //
PRNEWSWIRE
Amag to divest two of three women`s health drugs, CEO to step down
10 Jan 2020 //
REUTERS
Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society
16 Oct 2019 //
BIOSPACE
Embattled AMAG braces for October FDA Makena adcom, but it need not worry
24 Sep 2019 //
ENDPTS
AMAG, activist investor lock horns amid board takeover attempt
24 Sep 2019 //
FIERCE PHARMA
AMAG Pharma introduces Vyleesi for treatment of acquired, generalized HSDD
28 Aug 2019 //
PHARMABIZ
Amag`s female libido injectable therapy to sell at $899
07 Aug 2019 //
REUTERS
How the Pharmaceutical Industry is Looking to Treat Low Sex Drive
10 Jul 2019 //
BIOSPACE
AMAG wins FDA nod for Vyleesi
22 Jun 2019 //
FIERCE PHARMA
AMAG Pharmaceuticals` Vyleesi (Bremelanotide) Receives Approval in US
21 Jun 2019 //
FDA
Promise Pharmacy Receives FDA Form 483
18 Dec 2018 //
FDA
FDA alerts Not to use Promise Pharmacy`s drugs intended to be sterile
07 Dec 2018 //
FDA
Promise Pharmacy Receives FDA Form 483
30 Oct 2018 //
FDA
Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
04 Jun 2018 //
PR NEWSWIRE
Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
30 Dec 2014 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.